References and bibliography

Filter by: Author: Author… Achenbach, H Alder, JF Anderson, G Anderson, GM Anderson, LL Archer, RP Böszörményi, Z Bailey, K Baker, AW Baker, GB Barfknecht, CF Barker, EL Bastos, ML Bates, DK Baumberger, F Beaton, JM Beck, O Bej, AJ Benington, F Benirschke, M Benowitz, NL Bielt, JH Bigwood, J Blair, JB Bondarev, ML Bopp, BA Bossart, JF Braden, MR Bradley, RJ Branco, PS Braun, G Braun, U Brennan, M Brewster, WK Brown, CR Bruhn, JG Buchanan, JF Budinger, TF Buffum, JC Bunnell, S Burris, K Butterick, JR By, AW Caldicott, DGE Callaway, JC Callery, PS Camilleri, A Cannon, JG Cao, R Capela, JP Caputo, JF Carroll, FI Carter, MF Carvalho, F Cassels, B Cassels, BK Cassels, SSBK Castagnoli, N Castagnoli,Neal, CCST Castillo, M Cavanagh, RL Chamberlain, JH Chambers, JJ Chang-Fong, J Chapman, NB Chemel, BR Chilton, WS Cimbura, G Clement, BA Colado, MI Conarty, PF Cook, VJ Cooks, RG Coutts, RT Cozzi, NV Cumbay, MG Dér, P Dal Cason, TA Daley, PF Daly, JW Davis, DV Davis, S Desantis, F Dirnagl, U Domelsmith, LN Dowd, CS Dryer., SE DuPre, A Dudlettes, SD Duhaime, R Dyer, DC Eaton, TA Eckler, JR Egan, C El-Seedi, HR Elias-Baker, BA Elliott, JM Emrich, HM Engelbrecht, JA Faillace, LA Faillace., LA Falk, EM Feih, JT Ferguson, WJ Fernandes, E Ferreira, LM Fesik, SW Fierro, A Finley, NN Flynn, JR Forbes, TDA Frederick, SL Freeman, S Frescas, S Frescas, SP Fritschi, G Fukushima, S Fuller, RW Gagné, DR Gal, EM Gallardo-Godoy, A Galloway, G Gerasimov, M Gerdes, JM Gessner, PK Gibson, WC Gillespie, HK Girreser, U Glennon, RA Goff, CM Gohda, A Goodman, D Goodwin, WR Gopalakrishnan, A Green, AR Greenberg, DM Greenshaw, AJ Grob, CS Grotjahn, DB Guan, AM Gudelsky, GA Guinaudeau, H Gylys, JA Hadorn, M Hall, SM Halpern, JH Hamada, A Hasegawa, A Hathaway, BA Hayashi, T Hearst, E Hec, P Hegadoren, KM Helfrich, JS Helisten, C Herning, RI Herrick-Davis, K Hintzen, A Hoffman, AJ Holava, HM Hollister, LE Honda, K Houk, KN Howell, HG Huang, X Inoue, H Israelstam, DM Iversen, L Iwata, Y Jacob, JN Jacob, P Jadhav, KP Jansen, KLR Jara, AN Jensen, NH Jensen, RE Johanson, CE Johnson, MP Johnston, MR Jones, RT Junge, T Kaeding, WW Kalant, H Kalbhen, DA Kamata, H Kamata, T Kanthasamy, A Kantor, RE Katagi, M Keil, RN Kenaga, EE Kerlinger, HO Khorana, N Kidd, S Kier, LB Kimoto, S Kishi, T Kleinc, B Kline, TB Kollman, PA Kornfeld, H Kostuba, LJ Kothari, PJ Kraemer, T Kumaran, G Kuroki, H Kurrasch, D Kurrasch, DM Kurrasch-Orbaugh, D Kurrasch-Orbaugh, DM Kusubov, N Kuwayama, K Laban, U Landaw, SA Lau, D Lavanier, GL Lawler, CP Lee, FGH Lee, R Lee, S Lemaire, D Leung, AY Levine, B Levy, CK Lewin, AH Lewis, ER Lewis, MM Liang, G Lien, OG Lloyd, DH Lobo, AM Lodge, BA Long, JP Lowy, MT Lucaites, VL MacLean, DE Macedo, C Macnicol, MF Mailman, RB Makriyannis, A Malicky, JL Manian, AA Marona-Lewicka, D Martin, BR Martin-lverson, MT Mathis, CA Matoba, R Maurer, HH McBride, MC McGeorge, F McKenna, DJ McLaughlin, JL McLean, TH Mckay, JB Meatherall, R Mechan, AO Meisel, A Menachery, MD Meshul, CK Meyer, BN Miller, DD Mitome, T Miyaguchi, H Mohri, H Monte, A Monte, AP Moore, KA Morency, C Morin, RD Munro, TA Murdock, JE Naranjo, C Nash, JF Naylor, JC Nelson, DL Neve, KA Nichols, CD Nichols, DE Nichols, MB Nieforth, KA Nohr, ML Nuang, X O’Shea, E Oberlender, R Oberlender, RA Osorio-Olivares, M Ott, J Panaccione, DG Parker, MA Parkhursrt, RM Parrish, JC Partyka, RA Passie, T Patty, JR Paul, AG Pauli, M Pease, JP Peng, W Peretz, DI Perez, JA Perry, WE Petrakis, NL Pfaff, RC Pfister, WR Pike, RK Prast, CJ Prescher, JA Pummangura, S Putney, F Qandil, AM Quednow, B Rösner, P Rabin, RA Ramachandran, PV Ranieri, RL Rehder, KS Remião, F Repke, DB Reyes-Parada, M Rezende, MC Rhee, G Richelson, E Riggs, RM Rodríguez, GJ Roman, DL Roth, BL Rozeboom, MD Ruoho, AE Rusterholz, DB Saavedra, JM Saldaña, SN Sanders-Bush, E Sard, H Sargent, T Sargent, TW Saunders, A Saunders, N Savanapridi, C Schardl, CL Schifferdecker, RC Schneider, U Schultes, RE Schultz, DM Scrowston, RM Seifert, J Selken, J Shamma, M Shima, N Shulgin, A Shulgin, AT Shulgin, LA Shuster, L Shybut, G Sievert, MK Silversteinax, M Skinne, DWA Sklerov, JH Smith, C Smolinske, S Smythies, JR Snyder, SE Snyder, SH Soin, S Somei, M Sprague, JE Springer, D Staack, RF Standridge, RT Stauffer, H Steele, TD Stephanson, N Stichtenoth, DO Stolaroff, MJ Sutton,, TM Szara, S Tamura, M Tanaka, E Tanner, NS Teitler, M Tilson, HA Toad Tobin, MB Tomaszewski, Z Torrenegra, R Torres, MA Toth, BA Towers, HHN Trachsel, D Trout, K Tsuchihashi, H Tsujikawa, K Tsumura, Y Tudzynski, P Tupper, KW Unrau, AM Vangveravong, S Vourlekis, A Wainscott, DB Waldman, SR Wang, Z Wasson, RG Watts, VJ Weingartner, H Weintraub, HJR Wells, CW Westphal, F Wetherly, ML White, KJ White, TJ Whiteside, MS Wilson, JM Wilson, M Wilson, WL Winter, JC Wolters, RJ Woodard, R Woolverton, WL Xu, A Yamada, F Yano, Y Yim, GKW Yim, GRW Young, R Yu, A Yu, L Zabik, JE Zaitsu, K Zhong, D Journal: Journal… 4-Acetoxy-DET Vault 4-Acetoxy-DiPT Vault AAPS PharmSci Acta Pharm. Suec. Addict. Biol. Alkaloids Chem. Biol. Am. J. Public Health Amer. Chem. Soc. Div. Med. Chem. Abs. Anal. Chem. Analog Ann. N.Y. Acad. Sci. Appl. Radiat. Isot. Arzneim. Forsch. Ask Dr. Shulgin Online Biochem. Biophys. Res. Commun. Biol. Psychiat. Bioorg. Med. Chem. Bioorg. Med. Chem. Lett. Bull. Narc. CMAJ CNS Neurosci. Ther. Can. J. Chem. Can. Med. Assoc. J. Chem. Biodiv. Chem. Commun. (London) Chem. Pharm. Bull. Chem. Rev. Clin. Toxicol. Commun. Psychopharmacol. Curr. Med. Chem. DPT Vault Drug Policy Letter Eur. J. Med. Chem. Eur. J. Pharmacol. Experientia Forens. Sci. Intl. Helv. Chim. Acta IRCS (Int. Res. Comm. Sys.) Int. J. Neuropharmacol. J Forensic Sci. J. Accid Emerg Med. J. Agric. Food Chem. J. Am. Chem. Soc J. Anal. Tox. J. Anal. Toxicol. J. Assoc. Off. Anal. Chem. J. Chem. Soc. J. Chem. Soc., Perkin Trans. J. Chromatogr. J. Chromatogr. Biomed. Applic. J. Fluorine Chem. J. Forensic Sci. J. Forensic Sci. Soc. J. Heterocycl. Chem. J. Labelled Comp. and Radiopharm. J. Med. Chem. J. Mental Sci. J. Nat. Prod. J. Nerv. Ment. Dis. J. Neural. Transm. J. Nucl. Med. J. Org. Chem. J. Pharm. Pharmacol. J. Pharm. Sci. J. Pharmacol. Exp. Ther. J. Psychedelic Drugs J. Psychiatry Neurosci. J. Psychoactive Drugs Jahrbuch für Ethnomedizin und Bewußtseinsforschung (Yearbook of Ethnomedicine and the Study of Consciousness) LIFE Life Sci. Life Sciences Lloydia Med. Pharmacol. Exp. Med. Toxicol. Adverse. Drug. Exp. Meth. Find. Exp. Clin. Pharmacol. Microgram Mind Mol. Pharmacol. Mutat. Res. Nature Naturwissenschaften Neuropharmacology Neurosci. Res. Program Bull. Neuroscience PharmChem Newsletter Pharmacol. Rev. Pharmacol. Ther. Pharmacol., Biochem. Behav. Pharmacology Phytochemistry Proc. Natl. Acad. Sci. Psychopharmacol. Commun. Psychopharmacology Reality Hackers Recl. Trav. Chim. Pays-Bas-J. Roy. Neth. Chem. Soc. San Jose Mercury News Soc. Neurosci. Abs. Social Pharmacology Spectrochim. Acta Synth. Commun. Synthesis Tech. Rev. Tetrahedron Lett. Ther. Drug Monit. From: From… 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 To: To… 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010   Clear all filters

Sort by: Author then by: Author Title Title Publication Publication Newest to oldest Newest to oldest Oldest to newest Oldest to newest

Iversen, L. Consideration of the naphthylpyrovalerone analogues and related compounds, Advisory Council on the Misuse of Drugs (ACMD), 7 Jul 2010.

Iversen, L. Consideration of the cathinones, Advisory Council on the Misuse of Drugs (ACMD), 31 Mar 2010.

Camilleri, A; Johnston, MR; Brennan, M; Davis, S; Caldicott, DGE. Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, α-phthalimidopropiophenone and N-ethylcathinone. Forens. Sci. Intl., 2010, in press. 736 kB. doi:10.1016/j.forsciint.2009.12.048

Cozzi, NV; Gopalakrishnan, A; Anderson, LL; Feih, JT; Shulgin, AT; Daley, PF; Ruoho, AE. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J. Neural. Transm., 1 Dec 2009, 116 (12), 1591–1599. 420 kB. doi:10.1007/s00702-009-0308-8

Archer, RP. Fluoromethcathinone, a new substance of abuse. Forens. Sci. Intl., 2009, 185 (1–3), 10–20. 1355 kB. doi:10.1016/j.forsciint.2008.11.013

Yu, A. Indolealkylamines: Biotransformations and potential drug-drug interactions. AAPS PharmSci, 1 Jun 2008, 10 (2), 242–253. 314 kB. doi:10.1208/s12248-008-9028-5

Trachsel, D; Nichols, DE; Kidd, S; Hadorn, M; Baumberger, F. 4-Aryl-substituted 2,5-dimethoxyphenethylamines: Synthesis and serotonin 5-HT2A receptor affinities. Chem. Biodiv., 28 May 2008, 6 (5), 692–704. 271 kB. doi:10.1002/cbdv.200800235

Bruhn, JG; El-Seedi, HR; Stephanson, N; Beck, O; Shulgin, AT. Ecstasy analogues found in cacti. J. Psychoactive Drugs, 2008, 40 (2), 219–222. 223 kB.

Nichols, DE; Frescas, SP; Chemel, BR; Rehder, KS; Zhong, D; Lewin, AH. High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): A high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorg. Med. Chem., 2008, 16 (10), 6116–6123. 251 kB. doi:10.1016/j.bmc.2008.04.050

Nichols, DE; Nichols, CD. Serotonin receptors. Chem. Rev., 2008, 108 (5), 1614–1641. 2918 kB. doi:10.1021/cr078224o

Parker, MA; Kurrasch, DM; Nichols, DE. The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg. Med. Chem., 2008, 16 (8), 4661–4669. 296 kB. doi:10.1016/j.bmc.2008.02.033

Passie, T; Halpern, JH; Stichtenoth, DO; Emrich, HM; Hintzen, A. The pharmacology of lysergic acid diethylamide: A review. CNS Neurosci. Ther., 2008, 14 (4), 295–314. 690 kB. doi:10.1111/j.1755-5949.2008.00059.x

Schultz, DM; Prescher, JA; Kidd, S; Marona-Lewicka, D; Nichols, DE; Monte, A. ‘Hybrid’ benzofuran–benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. Bioorg. Med. Chem., 2008, 16 (11), 6242–6251. 228 kB. doi:10.1016/j.bmc.2008.04.030

Braden, MR. Towards a biophysical basis of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 2007. 8442 kB.

Braden, MR; Nichols, DE. Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Mol. Pharmacol., 2007, 72 (5), 1200–1209. 487 kB. doi:10.1124/mol.107.039255

Cao, R; Peng, W; Wang, Z; Xu, A. β-Carboline alkaloids: Biochemical and pharmacological functions. Curr. Med. Chem., 2007, 14 (4), 479–500. 579 kB. doi:10.2174/092986707779940998

Capela, JP; Macedo, C; Branco, PS; Ferreira, LM; Lobo, AM; Fernandes, E; Remião, F; Bastos, ML; Dirnagl, U; Meisel, A; Carvalho, F. Neurotoxicity mechanisms of thioether Ecstasy metabolites. Neuroscience, 2007, 146, 1743–1757. 995 kB. doi:10.1016/j.neuroscience.2007.03.028

Marona-Lewicka, D; Nichols, DE. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacol., Biochem. Behav., 2007, 87 (4), 453–461. 266 kB.

Selken, J; Nichols, DE. α1-Adrenergic receptors mediate the locomotor response to systemic administration of (±)-3,4-methylenedioxymethamphetamine (MDMA) in rats. Pharmacol., Biochem. Behav., 2007, 86 (4), 622–630. 1005 kB. doi:10.1016/j.pbb.2007.02.006

Westphal, F; Junge, T; Rösner, P; Fritschi, G; Kleinc, B; Girreser, U. Mass spectral and NMR spectral data of two new designer drugs with an α-aminophenone structure: 4′-Methyl-α-pyrrolidinohexanophenone and 4′-methyl-α-pyrrolidinobutyrophenone. Forens. Sci. Intl., 2007, 169 (1), 32–42. 1465 kB. doi:10.1016/j.forsciint.2006.07.024

Zaitsu, K; Katagi, M; Kamata, T; Kamata, H; Shima, N; Tsuchihashi, H; Hayashi, T; Kuroki, H; Matoba, R. Determination of a newly encountered designer drug “p-methoxyethylamphetamine” and its metabolites in human urine and blood. Forens. Sci. Intl., 2007, 177 (1), 77–84. 226 kB. doi:10.1016/j.forsciint.2007.11.001

Callaway, JC; Grob, CS; McKenna, DJ; Nichols, DE; Shulgin, AT; Tupper, KW; Sklerov, JH; Levine, B; Moore, KA. A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation. J. Anal. Toxicol., 1 Jul 2006, 30 (6), 406–407. 53 kB.

Trachsel, D; Hadorn, M; Baumberger, F. Synthesis of fluoro analogues of 3,4-(methylenedioxy)amphetamine (MDA) and Its derivatives. Chem. Biodiv., 23 Mar 2006, 3 (3), 326–336. 106 kB. doi:10.1002/cbdv.200690035

Braden, MR; Parrish, JC; Naylor, JC; Nichols, DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol. Pharmacol., 2006, 70 (6), 1956–1964. 361 kB. doi:10.1124/mol.106.028720

McLean, TH; Chambers, JJ; Parrish, JC; Braden, MR; Marona-Lewicka, D; Kurrasch-Orbaugh, D; Nichols, DE. C-(4,5,6-trimethoxyindan-1-yl)methanamine: A mescaline analogue designed using a homology model of the 5-HT2A receptor. J. Med. Chem., 2006, 49 (14), 4269–4274. 370 kB. doi:10.1021/jm060272y

McLean, TH; Chambers, JJ; Parrish, JC; Braden, MR; Marona-Lewicka, D; Kurrasch-Orbaugh, D; Nichols, DE. C-(4,5,6-trimethoxyindan-1-yl)methanamine: A mescaline analogue designed using a homology model of the 5-HT2A receptor (additions and corrections). J. Med. Chem., 2006, 49 (25), 7558–7558. 51 kB. doi:10.1021/jm0612259

McLean, TH; Parrish, JC; Braden, MR; Marona-Lewicka, D; Gallardo-Godoy, A; Nichols, DE. 1-Aminomethylbenzocycloalkanes: Conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J. Med. Chem., 2006, 49 (19), 5794–5803. 522 kB. doi:10.1021/jm060656o

Munro, TA. The chemistry of Salvia divinorum. Ph. D. Thesis, University of Melbourne, Australia, 2006. 6664 kB.

Parrish, JC. Toward a molecular understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 2006. 5567 kB.

Schardl, CL; Panaccione, DG; Tudzynski, P. Ergot alkaloids—Biology and molecular biology. Alkaloids Chem. Biol., 2006, 63, 45–86. 559 kB. doi:10.1016/S1099-4831(06)63002-2

Tanaka, E; Kamata, T; Katagi, M; Tsuchihashi, H; Honda, K. A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy. Forens. Sci. Intl., 2006, 163 (1), 152–154. 105 kB. doi:10.1016/j.forsciint.2005.11.026

Tsujikawa, K; Mohri, H; Kuwayama, K; Miyaguchi, H; Iwata, Y; Gohda, A; Fukushima, S; Inoue, H; Kishi, T. Analysis of hallucinogenic constituents in Amanita mushrooms circulated in Japan. Forens. Sci. Intl., 2006, 164 (2–3), 172–178. 634 kB. doi:10.1016/j.forsciint.2006.01.004

Shulgin, AT. 4-Hydroxy-5-methoxy-N,N-dimethyltryptamine, Psilocybe mushrooms, Psilocin. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 7 Dec 2005.

Shulgin, AT. Psychedelic science—How to prepare. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 2 Jun 2005.

Shulgin, AT. DOB and other possible prodrugs. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 3 May 2005.

Shulgin, AT. Ice, crank, speed or methamphetamine. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 6 Apr 2005.

Shulgin, AT. Drug testing hair for MDMA (Ecstasy). @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 4 Mar 2005.

Shulgin, AT. Juul’s giant cactus (aka Jewel’s giant). @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 4 Jan 2005.

Gallardo-Godoy, A; Fierro, A; McLean, TH; Castillo, M; Cassels, BK; Reyes-Parada, M; Nichols, DE. Sulfur-substituted α-alkyl phenethylamines as selective and reversible MAOA inhibitors: Biological activities, CoMFA analysis, and active site modeling. J. Med. Chem., 2005, 48 (7), 2407–2419. 901 kB. doi:10.1021/jm0493109

Sard, H; Kumaran, G; Morency, C; Roth, BL; Toth, BA; Hec, P; Shuster, L. SAR of psilocybin analogs: Discovery of a selective 5-HT2C agonist. Bioorg. Med. Chem. Lett., 2005, 15 (20), 4555–4599. 134 kB. doi:10.1016/j.bmcl.2005.06.104

Shulgin, AT. Abused substances. Tech. Rev., 2005, August, 80–81. 415 kB.

Tsumura, Y; Mitome, T; Kimoto, S. False positives and false negatives with a cocaine-specific field test and modification of test protocol to reduce false decision. Forens. Sci. Intl., 2005, 155 (2), 158–164. 320 kB. doi:10.1016/j.forsciint.2004.11.011

Wilson, JM; McGeorge, F; Smolinske, S; Meatherall, R. A foxy intoxication. Forens. Sci. Intl., 2005, 148 (1), 31–36. 160 kB. doi:10.1016/j.forsciint.2004.04.017

Shulgin, AT. Cathinone. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 3 Jun 2004.

McKenna, DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol. Ther., 1 May 2004, 102 (2), 111–129. doi:10.1016/j.pharmthera.2004.03.002

Maurer, HH; Kraemer, T; Springer, D; Staack, RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (Ecstasy), piperazine, and pyrrolidinophenone types. A synopsis. Ther. Drug Monit., 1 Apr 2004, 26 (2), 127–131. 121 kB.

Shulgin, AT. Yaba (methamphetamine). @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 9 Mar 2004.

Shulgin, AT. LSD and pregnancy. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 28 Jan 2004.

Glennon, RA; Bondarev, ML; Khorana, N; Young, R. β-Oxygenated analogues of the 5-HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. J. Med. Chem., 2004, 47 (24), 6034–6041. 146 kB. doi:10.1021/jm040082s

Halpern, JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol. Ther., 2004, 102 (2), 131–138. 202 kB. doi:10.1016/j.pharmthera.2004.03.003

Nichols, DE. Hallucinogens. Pharmacol. Ther., 2004, 101 (2),131–181. 855 kB. doi:10.1016/j.pharmthera.2003.11.002

Osorio-Olivares, M; Rezende, MC; Cassels, SSBK; Fierro, A. MAO inhibition by arylisopropylamines: the effect of oxygen substituents at the β-position. Bioorg. Med. Chem., 2004, 12 (15), 4055–4066. 412 kB. doi:10.1016/j.bmc.2004.05.033

Rösner, P; Quednow, B; Girreser, U; Junge, T. Isomeric fluoro-methoxy-phenylalkylamines: A new series of controlled-substance analogues (designer drugs). Forens. Sci. Intl., 2004, 148 (2–3), 143–156. 282 kB. doi:10.1016/j.forsciint.2004.05.003

Rodríguez, GJ; Roman, DL; White, KJ; Nichols, DE; Barker, EL. Distinct recognition of substrates by the human and Drosophila serotonin transporters. J. Pharmacol. Exp. Ther., 2004, 306 (1), 338–346. 452 kB. doi:10.1024/jpet.103.048751

Roman, DL; Saldaña, SN; Nichols, DE; Carroll, FI; Barker, EL. Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters. J. Pharmacol. Exp. Ther., 2004, 308 (2), 679–687. 519 kB. doi:10.1024/jpet.103.057836

Shulgin, AT. Mushrooms and aeruginascin. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 21 Oct 2003.

Shulgin, AT. On the question of marijuana safety. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 22 Sep 2003.

Trachsel, D. Synthesis of novel (phenylalkyl)amines for the investigation of structure-activity relationships. Part 3. 4-Ethynyl-2,5-dimethoxyphenethylamine (= 4-Ethynyl-2,5-dimethoxybenzeneethanamine; 2C-YN). Helv. Chim. Acta, 28 Aug 2003, 86 (8), 2754–2759. 84 kB. doi:10.1002/hlca.200390224

Trachsel, D. Synthesis of novel (phenylalkyl)amines for the investigation of structure-activity relationships. Part 2. 4-Thio-substituted [2-(2,5-dimethoxyphenyl)ethyl]amines (=2,5-dimethoxybenzeneethanamines). Helv. Chim. Acta, 5 Aug 2003, 86 (7), 2610–2619. 133 kB. doi:10.1002/hlca.200390210

Shulgin, AT. Salvia divinorum, law, and medicine. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 23 Jul 2003.

Shulgin, AT. DXM (dextromethorphan). @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 9 Jul 2003.

Shulgin, AT. MDMA and its methylenedioxy ring. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 3 Jun 2003.

Shulgin, AT. MDMA variations & freedom of inquiry. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 24 Apr 2003.

Shulgin, AT. MMDA (MMDA-4). @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 11 Apr 2003.

Shulgin, AT. TMA, PMA, PMMA, and MDMA effects. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 27 Mar 2003.

Shulgin, AT. The Secret Chief and MAPS. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Mar 2003.

Shulgin, AT. Psilocybe mushroom extractions. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 5 Mar 2003.

Shulgin, AT. Oxycontin, oxycodone, heroin. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 20 Feb 2003.

Shulgin, AT. 2,5-Dimethoxy-4-bromophenethylamine (2C-B). @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 7 Feb 2003.

Shulgin, AT. Taking MDMA (Ecstasy) and other drugs when pregnant. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 28 Jan 2003.

Chambers, JJ; Parrish, JC; Jensen, NH; Kurrasch-Orbaugh, DM; Marona-Lewicka, D; Nichols, DE. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT2A/2C receptor ligands. J. Med. Chem., 2003, 46 (16), 3526–3535. 423 kB. doi:10.1021/jm030064v

Eckler, JR; Chang-Fong, J; Rabin, RA; Smith, C; Teitler, M; Glennon, RA; Winter, JC. Behavioral characterization of 2-O-desmethyl and 5-O-desmethyl metabolites of the phenylethylamine hallucinogen DOM. Pharmacol., Biochem. Behav., 2003, 75 (4), 845–852. 294 kB. doi:10.1016/S0091-3057(03)00159-X

Green, AR; Mechan, AO; Elliott, JM; O’Shea, E; Colado, MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”). Pharmacol. Rev., 2003, 55 (3, 463–508). 544 kB. doi:10.1124/pr.55.3.3

Shulgin, AT. Datura, thornapple, atropine & scopolamine. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 31 Dec 2002.

Shulgin, AT. 5-Me-DMT or 5,N,N-TMT (5,N,N-trimethyltryptamine). @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 18 Nov 2002.

Shulgin, AT. Morning glory seeds. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 17 Oct 2002.

Shulgin, AT. DMT and tryptophan. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 19 Sep 2002.

Shulgin, AT. Ecstasy pill testing. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Sep 2002.

Shulgin, AT. Poppers. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 2 Aug 2002.

Shulgin, AT. Salvinorin A and the Analogue Act. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Jul 2002.

Trachsel, D. Synthesis of novel (phenylalkyl)amines for the investigation of structure-activity relationships. Part 1. Mescalin derivatives. Helv. Chim. Acta, 21 Jun 2002, 85 (9), 3019–3026. 98 kB. doi:10.1002/1522-2675(200209)85:9<3019::AID-HLCA3019>3.0.CO;2-4

Shulgin, AT. Future psychedelics. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Jun 2002.

Shulgin, AT. Salvinorin A. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 22 May 2002.

Shulgin, AT. Making MDMA (II): “Ecstasy”, MDMA, & Safrole. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 1 May 2002.

Shulgin, AT. MDMA (Ecstasy) tolerance. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 10 Apr 2002.

Shulgin, AT. Trimethoxylated amphetamine derivatives. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 14 Mar 2002.

Shulgin, AT. 5-Methoxy-N-ethyl-N-isopropyltryptamine, 5-MeO-MIPT, 5-MeO-DIPT, 5-MeO-EIPT. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 27 Feb 2002.

Shulgin, AT. Ayahuasca and MAO inhibitors. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Feb 2002.

Shulgin, AT. Salvia divinorum and Salvinorin-A receptor sites. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 9 Jan 2002.

Chambers, JJ. Use of conformationally-restricted analogues and homology modeling to provide insight into the nature of the 5-HT2A receptor agonist binding site. Ph. D. Thesis, Purdue University, West Lafayette, IN, 2002. 11931 kB.

Chambers, JJ; Kurrasch-Orbaugh, DM; Nichols, DE. Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: Effects on 5-HT2A/2C receptor affinity. Bioorg. Med. Chem. Lett., 2002, 12 (15), 1997–1999. 100 kB. doi:10.1016/S0960-894X(02)00306-2

Falk, EM; Cook, VJ; Nichols, DE; Sprague, JE. An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacol., Biochem. Behav., 2002, 72 (3), 617–622. 120 kB. doi:10.1016/S0091-3057(02)00728-1

Freeman, S; Alder, JF. Arylethylamine psychotropic recreational drugs: A chemical perspective. Eur. J. Med. Chem., 2002, 37 (7), 527–539. 256 kB. doi:10.1016/S0223-5234(02)01382-X

Nichols, DE; Frescas, S; Marona-Lewicka, D; Kurrasch-Orbaugh, DM. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). J. Med. Chem., 2002, 45 (19), 4344–4349. 268 kB. doi:10.1021/jm020153s

Passie, T; Seifert, J; Schneider, U; Emrich, HM. The pharmacology of psilocybin. Addict. Biol., 2002, 7 (4), 357–364. 184 kB. doi:10.1080/135562102100000593

Shulgin, AT; Perry, WE. The Simple Plant Isoquinolines, Transform Press: Berkeley, CA, 2002.

Whiteside, MS; Kurrasch-Orbaugh, D; Marona-Lewicka, D; Nichols, DE; Monte, A. Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes. Bioorg. Med. Chem., 2002, 10 (10), 3301–3306. 141 kB. doi:10.1016/S0968-0896(02)00209-2

Yamada, F; Tamura, M; Hasegawa, A; Somei, M. Synthetic studies of psilocin analogs having either a formyl group or bromine atom at the 5- or 7-position. Chem. Pharm. Bull., 2002, 50 (1) 92—99. 107 kB.

Shulgin, AT. Salvia divinorum cuttings. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Dec 2001.

Shulgin, AT. Psychedelics and anaesthetics. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 29 Nov 2001.

Shulgin, AT. Peyote and MAO inhibitors. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 14 Nov 2001.

Shulgin, AT. MDMA (Ecstasy) and holes in the brain. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 30 Oct 2001.

Shulgin, AT. MDMA (Ecstasy) testing and Marquis reagent. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 5 Oct 2001.

Shulgin, AT. Acacias and natural amphetamine. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 21 Sep 2001.

Shulgin, AT. Roadblocks to entheogen research. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 12 Sep 2001.

Ott, J. Pharmanopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J. Psychoactive Drugs, 1 Sep 2001, 33 (3), 273–281. 145 kB.

Shulgin, AT. MDMA isomers. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 27 Aug 2001.

Shulgin, AT. Favorite music. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 14 Aug 2001.

Shulgin, AT. Salvia divinorum seeds and growing. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 20 Jul 2001.

Shulgin, AT. Entheogens—significance and future. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 11 Jul 2001.

Shulgin, AT. 2C-T-7. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 28 Jun 2001.

Shulgin, AT. Entheogens and education. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 30 May 2001.

Shulgin, AT. Tryptamines in Phalaris & phenethylamines in cacti. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 15 May 2001.

Shulgin, AT. Thought policing MDMA users (AB 1416). @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 20 Apr 2001.

Shulgin, AT. THC and Lichens. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 2 Apr 2001.

Shulgin, AT. Making MDA, MDEA, MDMA. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 15 Mar 2001.

Shulgin, AT. Parahexl. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 7 Mar 2001.

Shulgin, AT. LSD Flashbacks. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 1 Mar 2001.

Shulgin, AT. PMA. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 20 Feb 2001.

Shulgin, AT. MDMA (Ecstasy) v. Methamphetamine. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 15 Feb 2001.

Buffum, JC; Shulgin, AT. Overdose of 2.3 grams of intravenous methamphetamine: Case, analysis and patient perspective. J. Psychoactive Drugs, 2001, 33 (4), 409–412. 284 kB.

Chambers, JJ; Kurrasch-Orbaugh, DM; Parker, MA; Nichols, DE. Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT2A/2C receptor agonists. J. Med. Chem., 2001, 44 (6), 1003–1010. 337 kB. doi:10.1021/jm000491y

Dal Cason, TA. A re-examination of the mono-methoxy positional ring isomers of amphetamine, methamphetamine and phenyl-2-propanone. Forens. Sci. Intl., 2001, 119 (3), 168–194. 678 kB. doi:10.1016/S0379-0738(00)00425-4

Kalant, H. The pharmacology and toxicology of “Ecstasy” (MDMA) and related drugs. CMAJ, 2001, 165 (7), 917–928. 253 kB.

Laban, U; Kurrasch-Orbaugh, D; Marona-Lewicka, D; Nichols, DE. A novel fluorinated tryptamine with highly potent serotonin 5-HT1A receptor agonist properties. Bioorg. Med. Chem. Lett., 2001, 11 (6), 793–795. 102 kB. doi:10.1016/S0960-894X(01)00062-2

Shulgin, AT. A Scientist’s View of Miracles and Magic. In Psychoactive Sacramentals: Essays on Entheogens and Religion; Roberts, TB, Ed., Council on Spiritual Practice, San Franciscos, 2001; pp 113–119.

Toad. 4-Acetoxy-DET Primer. @ 4-Acetoxy-DET Vault, Erowid, 2001.

Blair, JB; Kurrasch-Orbaugh, D; Marona-Lewicka, D; Cumbay, MG; Watts, VJ; Barker, EL; Nichols, DE. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J. Med. Chem., 2000, 43 (24), 4701–4710. 494 kB. doi:10.1021/jm000339w

McBride, MC. Bufotenine: Toward an understanding of possible psychoactive mechanisms. J. Psychoactive Drugs, 2000, 32 (3), 321–331. 959 kB.

Saunders, N; Saunders, A; Pauli, M. In Search of the Ultimate High. In Preface; Rider, London, 2000; pp 7–9.

Toad. 4-Acetoxy-DiPT Primer. @ 4-Acetoxy-DiPT Vault, Erowid, 1 Nov 1999.

Blair, JB; Marona-Lewicka, D; Kanthasamy, A; Lucaites, VL; Nelson, DL; Nichols, DE. Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine. J. Med. Chem., 1999, 42 (6), 1106–1111. 129 kB. doi:10.1021/jm980692q

Cozzi, NV; Sievert, MK; Shulgin, AT; Jacob, P; Ruoho, AE. Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Eur. J. Pharmacol., 1999, 381 (1), 63–69. 111 kB. doi:10.1016/S0014-2999(99)00538-5

Gerasimov, M; Marona-Lewicka, D; Kurrasch-Orbaugh, DM; Qandil, AM; Nichols, DE. Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain. J. Med. Chem., 1999, 42 (20), 4257–4263. 163 kB. doi:10.1021/jm990325u

Jacob, P; Yu, L; Shulgin, AT; Benowitz, NL. Minor tobacco alkaloids as biomarkers for tobacco use: Comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am. J. Public Health, 1999, 89 (5), 731–736. 1737 kB.

Nichols, DE; Frescas, S. Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin. Synthesis, 1999, 1999, 935–938. 1481 kB. doi:10.1055/s-1999-3490

Toad. DPT Primer. @ DPT Vault, Erowid, 15 Nov 1998.

Shulgin, AT. Spoils of the Drug War. San Jose Mercury News, 10 Mar 1998. 5 kB.

Clement, BA; Goff, CM; Forbes, TDA. Toxic amines and alkaloids from Acacia rigidula. Phytochemistry, 1998, 49 (5), 1377–1380. 124 kB. doi:10.1016/S0031-9422(97)01022-4

Cozzi, NV; Frescas, S; Marona-Lewicka, D; Huang, X; Nichols, DE. Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential. Pharmacol., Biochem. Behav., 1998, 59 (3), 709–715. 110 kB. doi:10.1016/S0091-3057(97)00557-1

Lee, S. The total syntheses of ring-A substituted ergolines. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1998. 4709 kB.

Monte, AP; Marona-Lewicka, D; Lewis, MM; Mailman, RB; Wainscott, DB; Nelson, DL; Nichols, DE. Substituted naphthofurans as hallucinogenic phenethylamine—ergoline hybrid molecules with unexpected muscarinic antagonist activity. J. Med. Chem., 1998, 41 (12), 2134–2145. 258 kB. doi:10.1021/jm980076u

Parker, MA. Studies of perceptiotropic phenethylamines: Determinants of affinity for the 5-HT2A receptor. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1998. 3334 kB.

Parker, MA; Marona-Lewicka, D; Kurrasch, D; Shulgin, AT; Nichols, DE. Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA). J. Med. Chem., 1998, 41 (6), 1001–1005. 117 kB. doi:10.1021/jm9705925

Parker, MA; Marona-Lewicka, D; Lucaites, VL; Nelson, DL; Nichols, DE. A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. J. Med. Chem., 1998, 41 (26), 5148–5149. 81 kB. doi:10.1021/jm9803525

Vangveravong, S; Kanthasamy, A; Lucaites, VL; Nelson, DL; Nichols, DE. Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives. J. Med. Chem., 1998, 41 (25), 4995–5001. 140 kB. doi:10.1021/jm980318q

Achenbach, H; Benirschke, M; Torrenegra, R. Alkaloids and other compounds from seeds of Tabernaemontana cymosa. Phytochemistry, 1997, 45 (2), 325–335. 826 kB. doi:10.1016/S0031-9422(96)00645-0

Blair, JB. Synthesis and pharmacological evaluation of fluorinated hallucinogenic tryptamine analogs and thienopyrrole bioisosteres of N,N-dimethyltryptamine. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1997. 3958 kB.

Clement, BA; Goff, CM; Forbes, TDA. Toxic amines and alkaloids from Acacia berlandieri. Phytochemistry, 1997, 46 (2), 249–254. 435 kB. doi:10.1016/S0031-9422(97)00240-9

Dal Cason, TA. The characterization of some 3,4-methylenedioxycathinone (MDCATH) homologs. Forens. Sci. Intl., 1997, 87 (1), 9–53. 909 kB. doi:10.1016/S0379-0738(97)02133-6

Dal Cason, TA; Young, R; Glennon, RA. Cathinone: An investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol., Biochem. Behav., 1997, 58 (4), 1109–1116. 97 kB. doi:10.1016/S0091-3057(97)00323-7

Monte, AP; Waldman, SR; Marona-Lewicka, D; Wainscott, DB; Nelson, DL; Sanders-Bush, E; Nichols, DE. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J. Med. Chem., 1997, 40 (19), 2997–3008. 367 kB. doi:10.1021/jm970219x

Shulgin, AT; Shulgin, A. TiHKAL: The Continuation, Transform Press: Berkeley, CA, 1997.

Gerdes, JM; Keil, RN; Shulgin, AT; Mathis, CA. High pressure nucleophilic fluoride-ion substitution reactions: formation of fluoroalkylbenzenes. J. Fluorine Chem., 1996, 78 (2), 121–129. doi:10.1016/0022-1139(96)03417-3

Jacob, P; Shulgin, AT. Preparation of novel N-substituted-2-amino-3′,4′-methylenedioxypropiophenones as anti-depressant and anti-parkinsonism agents. International patent application PCT/US96/09603, 1996. 941 kB.

Marona-Lewicka, D; Rhee, G; Sprague, JE; Nichols, DE. Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol., Biochem. Behav., 1996, 53 (1), 99–105. 1028 kB. doi:10.1016/0091-3057(95)00205-7

Monte, AP; Marona-Lewicka, D; Parker, MA; Wainscott, DB; Nelson, DL; Nichols, DE. Dihydrobenzofuran analogues of hallucinogens. 3. 1 Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J. Med. Chem., 1996, 39 (15), 2953–2961. 290 kB. doi:10.1021/jm960199j

Galloway, G; Shulgin, AT; Kornfeld, H; Frederick, SL. Amphetamine, not MDMA, is associated with intracranial hemorrhage. J. Accid Emerg Med., 1995, 12 (3), 231–2. 428 kB. doi:10.1136/emj.12.3.231

Glennon, RA; Young, R; Martin, BR; Dal Cason, TA. Methcathinone (“Cat”): An enantiomeric potency comparison. Pharmacol., Biochem. Behav., 1995, 50(4) 601–606. 709 kB. doi:10.1016/0091-3057(94)00348-3

Marona-Lewicka, D; Rhee, G; Sprague, JE; Nichols, DE. Psychostimulant-like effects of p-fluoroamphetamine in the rat. Eur. J. Pharmacol., 1995, 287 (2), 105–113. 965 kB. doi:10.1016/0014-2999(95)00478-5

Monte, AP; Marona-Lewicka, D; Kanthasamy, A; Sanders-Bush, E; Nichols, DE. Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. J. Med. Chem., 1995, 38 (6), 958–966. 1156 kB. doi:10.1021/jm00006a015

Oberlender, R; Ramachandran, PV; Johnson, MP; Huang, X; Nichols, DE. Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines. J. Med. Chem., 1995, 38 (18), 3593–3601. 1288 kB. doi:10.1021/jm00018a019

Torres, MA; Cassels, B; Rezende, MC. The preparation of potentially psychoactive β-alkoxyphenethylamines. Synth. Commun., 1995, 25 (8), 1239–1247. 415 kB. doi:10.1080/00397919508012687

Vangveravong, S; Nichols, DE. Stereoselective synthesis of trans-2-(indol-3-yl)cyclopropylamines: Rigid tryptamine analogs. J. Org. Chem., 1995, 60 (11), 3409–3413. 654 kB. doi:10.1021/jo00116a028

Watts, VJ; Mailman, RB; Lawler, CP; Neve, KA; Nichols, DE. LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 1995, 118 (4), 401–409. 1367 kB. doi:10.1007/BF02245940

Hegadoren, KM; Greenshaw, AJ; Baker, GB; Martin-lverson, MT; Lodge, BA; Soin, S. 4-Ethoxyamphetamine: effects on intracranial self-stimulation and in vitro uptake and release of 3H-dopamine and 3H-serotonin in the brains of rats. J. Psychiatry Neurosci., 1994, 19 (1), 57–62. 910 kB.

Huang, X; Marona-Lewicka, D; Pfaff, RC; Nichols, DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol., Biochem. Behav., 1994, 47 (3), 667–673. 650 kB. doi:10.1016/0091-3057(94)90172-4

Jacob, P; Shulgin, AT. Structure-activity relationships of the classic hallucinogens and their analogs. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office: Washington, DC, 1994; pp 74–91. 51 kB.

Jara, AN; Torres, MA; Cassels, BK; Rezende, MC. Some fluoro and nitro analogues of hallucinogenic amphetamines. Synth. Commun., 1994, 24 (3), 417–426. 440 kB. doi:10.1080/00397919408011201

Marona-Lewicka, D; Nichols, DE. Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur. J. Pharmacol., 1994, 258 (1–2), 1–13. 1252 kB. doi:10.1016/0014-2999(94)90051-5

Nichols, DE. Medicinal chemistry and structure-activity relationships. In Amphetamine and its Analogs; Cho, AK; Segal, DS, Eds., Academic Press, San Diego, CA, 1994; pp 3–41. 6868 kB.

Nichols, DE; Frescas, S; Marona-Lewicka, D; Huang, X; Roth, BL; Gudelsky, GA; Nash, JF. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: A potent serotonin 5-HT2A/2C agonist. J. Med. Chem., 1994, 37 (25), 4346–4351. 873 kB. doi:10.1021/jm00051a011

Pfaff, RC; Huang, X; Marona-Lewicka, D; Oberlender, R; Nichols, DE. Lysergamides revisited. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office: Washington, DC, 1994; pp 52–73. 181 kB.

Sprague, JE; Huang, X; Kanthasamy, A; Nichols, DE. Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. Life Sci., 1994, 55 (15), 1193–1198. 336 kB. doi:10.1016/0024-3205(94)00658-X

Huang, X; Nichols, DE. 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur. J. Pharmacol., 1993, 238 (2–3), 291–296. 553 kB. doi:10.1016/0014-2999(93)90859-G

Jacob, P; Yu, L; Liang, G; Shulgin, AT; Benowitz, NL. Gas chromatographic-mass spectrometric method for determination of anabasine, anatabine and other tobacco alkaloids in urine of smokers and smokeless tobacco users. J. Chromatogr. Biomed. Applic., 1993, 619,49–61. 736 kB. doi:10.1016/0378-4347(93)80445-A

Monte, AP; Marona-Lewicka, D; Cozzi, NV; Nichols, DE. Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogs of 3,4-(methylenedioxy)amphetamine. J. Med. Chem., 1993, 36 (23), 3700–3706. 1026 kB. doi:10.1021/jm00075a027

Stolaroff, MJ; Wells, CW. Preliminary results with new psychoactive agents 2C-T-2 and 2C-T-7. Jahrbuch für Ethnomedizin und Bewußtseinsforschung (Yearbook of Ethnomedicine and the Study of Consciousness), 1993, 2, 99–117. 185 kB.

Huang, X; Marona-Lewicka, D; Nichols, DE. p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur. J. Pharmacol., 1992, 229 (1), 31–38. 702 kB. doi:10.1016/0014-2999(92)90282-9

Jacob, P; Shulgin, AT; Yu, L; Benowitz, NL. Determination of the nicotine metabolite trans-3′-hydroxycotinine in urine of smokers using gas chromatography with nitrogen-selective detection or selected ion monitoring. J. Chromatogr. Biomed. Applic., 1992, 583, 145–154. 608 kB. doi:10.1016/0378-4347(92)80547-4

Oberlender, R; Pfaff, RC; Johnson, MP; Huang, X; Nichols, DE. Stereoselective LSD-like activity in d-lysergic acid amides of R- and S-2-aminobutane. J. Med. Chem., 1992, 35 (2), 203–211. 1143 kB. doi:10.1021/jm00080a001

Shulgin, AT. Controlled Substances. A Chemical and Legal Guide to the Federal Drug Laws, 2nd ed., Ronin Publishing: Berkeley, CA, 1992.

Tomaszewski, Z; Johnson, MP; Huang, X; Nichols, DE. Benzofuran bioisosteres of hallucinogenic tryptamines. J. Med. Chem., 1992, 35 (11), 2061–2064. 591 kB. doi:10.1021/jm00089a017

By, AW; Duhaime, R; Lodge, BA. The synthesis and spectra of 4-ethoxyamphetamine and its isomers. Forens. Sci. Intl., 1991, 49 (2), 159–170. 494 kB. doi:10.1016/0379-0738(91)90075-T

Huang, X; Johnson, MP; Nichols, DE. Reduction in brain serotonin markers by α-ethyltryptamine (Monase). Eur. J. Pharmacol., 1991, 200 (1), 187–190. 420 kB. doi:10.1016/0014-2999(91)90686-K

Johnson, MP; Conarty, PF; Nichols, DE. [3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur. J. Pharmacol., 1991, 200 (1), 9–16. 1107 kB. doi:10.1016/0014-2999(91)90659-E

Johnson, MP; Frescas, SP; Oberlender, R; Nichols, DE. Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: Similarities to 3,4-(methylenedioxy)methamphetamine (MDMA). J. Med. Chem., 1991, 34 (5), 1662–1668. 975 kB. doi:10.1021/jm00109a020

Johnson, MP; Huang, X; Nichols, DE. Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue. Pharmacol., Biochem. Behav., 1991, 40 (4), 915–922. 845 kB. doi:10.1016/0091-3057(91)90106-C

Lodge, BA. Canadian designer drugs. J. Psychiatry Neurosci., 1991, 16 (5), 239–240.

McKenna, DJ; Guan, AM; Shulgin, AT. 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine. Pharmacol., Biochem. Behav., 1991, 38 (3), 505–12. 783 kB. doi:10.1016/0091-3057(91)90005-M

Nash, JF; Nichols, DE. Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. Eur. J. Pharmacol., 1991, 200 (1), 53–58. 714 kB. doi:10.1016/0014-2999(91)90664-C

Nichols, DE; Johnson, MP; Oberlender, R. 5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine. Pharmacol., Biochem. Behav., 1991, 38 (1), 135–139. 456 kB. doi:10.1016/0091-3057(91)90601-W

Nichols, DE; Oberlender, R; McKenna, DJ. Stereochemical aspects of hallucinogenesis. In Biochemistry and Physiology of Substance Abuse, Vol. 3; Watson, RR, Ed., CRC Press, Boca Raton, FL, 1991; . 44166 kB.

Nichols, DE; Snyder, SE; Oberlender, R; Johnson, MP; Huang, X. 2,3-Dihydrobenzofuran analogs of hallucinogenic phenethylamines. J. Med. Chem., 1991, 34 (1), 276–281. 833 kB. doi:10.1021/jm00105a043

Oberlender, R; Nichols, DE. Structural variation and (+)-amphetamine-like discriminative stimulus properties. Pharmacol., Biochem. Behav., 1991, 38 (3), 581–586. 586 kB. doi:10.1016/0091-3057(91)90017-V

Shulgin, AT. Future Drugs: The Next 10 Years. Drug Policy Letter, 1991, 8–10. 6000 kB.

Shulgin, AT. Designer drugs. Where we are, and where we are going. J. Forensic Sci. Soc., 1991, 31 (2), 231–232. 364 kB. doi:10.1016/S0015-7368(91)73146-0

Shulgin, AT; Shulgin, A. PiHKAL: A Chemical Love Story, Transform Press: Berkeley, CA, 1991.

Shulgin, AT; Shulgin, A; Jacob, P. Letter to the editor (re: 2C-T series). J. Psychoactive Drugs, 1991, 23 (1), 95–96. 2571 kB.

Steele, TD; Brewster, WK; Johnson, MP; Nichols, DE; Yim, GKW. Assessment of the role of α-methylepinine in the neurotoxicity of MDMA. Pharmacol., Biochem. Behav., 1991, 38 (2), 345–351. 723 kB. doi:10.1016/0091-3057(91)90289-E

Wilson, WL. The identification and analysis of Canadian designer drugs. J. Forensic Sci. Soc., 1991, 31 (2), 233–237. 538 kB. doi:10.1016/S0015-7368(91)73147-2

Dal Cason, TA. An evaluation of the potential for clandestine manufacture of 3,4-methylenedioxyamphetamine (MDA) analogs and homologs. J. Forensic Sci., 1 May 1990, 35 (3), 675–697. doi:10.1520/JFS12874J

Dowd, CS; Herrick-Davis, K; Egan, C; DuPre, A; Smith, C; Teitler, M; Glennon, RA. 1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT2A partial agonists. J. Med. Chem., 1 Mar 1990, 33 (3), 1032–1036. 271 kB. doi:10.1021/jm9906062

Shulgin, AT. How similar is substantially similar?. J Forensic Sci., 1 Jan 1990, 35 (1), 8–10. 410 kB. doi:10.1520/JFS12796J

Jacob, P; Jones, RT; Benowitz, NL; Shulgin, AT; Lewis, ER; Elias-Baker, BA. Cocaine smokers excrete a pyrolysis product, anhydroecgonine methyl ester. Clin. Toxicol., 1990, 28 (1), 123–125. 182 kB. doi:10.3109/15563659008993484

Jacob, P; Shulgin, AT; Benowitz, NL. Synthesis of (3′R,5′S)-trans-3′-hydroxycotinine, a major metabolite of nicotine. Metabolic formation of 3′-hydroxycotinine in humans is highly stereoselective. J. Med. Chem., 1990, 33 (7), 1888–1891. 590 kB. doi:10.1021/jm00169a009

Johnson, MP; Mathis, CA; Shulgin, AT; Hoffman, AJ; Nichols, DE. [125I]-2-(2,5-Dimethoxy-4-iodophenyl)aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex. Pharmacol., Biochem. Behav., 1990, 35 (1), 211–217. 724 kB. doi:10.1016/0091-3057(90)90228-A

Johnson, MP; Nichols, DE. Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine. Pharmacol., Biochem. Behav., 1990, 36 (1), 105–109. 521 kB. doi:10.1016/0091-3057(90)90133-3

Johnson, MP; Nuang, X; Oberlender, R; Nash, JF; Nichols, DE. Behavioral, biochemical and neurotoxicological actions of the α-ethyl homologue of p-chloroamphetamine. Eur. J. Pharmacol., 1990, 191 (1), 1–10. 1250 kB. doi:10.1016/0014-2999(90)94090-K

Nichols, DE; Brewster, WK; Johnson, MP; Oberlender, R; Riggs, RM. Nonneurotoxic tetralin and indan analogs of 3,4-(methylenedioxy)amphetamine (MDA). J. Med. Chem., 1990, 33 (2), 703–710. 1078 kB. doi:10.1021/jm00164a037

Nichols, DE; Oberlender, R. Structure-activity relationships of MDMA and related compounds: a new class of psychoactive agents?. In Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA; Peroutka, S, Ed., Kluwer Academic Publishers: Norwell, MA, 1990; . 5442 kB.

Shulgin, AT. Forensic Toxicology, University of California, BEHS 183, Kinko’s, Berekely, 1990.

Shulgin, AT. History of MDMA. In Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA; Peroutka, S, Ed., Kluwer Academic Publishers: Norwell, MA, 1990; . 3840 kB.

Stolaroff, MJ. Letter to the editor (re: 2C-T-2 & 2C-T-7). J. Psychoactive Drugs, 1990, 22 (3), 379. 1090 kB.

Johnson, MP; Nichols, DE. Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration. Pharmacol., Biochem. Behav., 1989, 33 (1), 105–108. 399 kB. doi:10.1016/0091-3057(89)90437-1

Nichols, DE; Oberlender, R. Structure-activity relationships of MDMA-like substances. In Pharmacology and Toxicology of Amphetamine and Related Designer Drugs. NIDA Research Monograph 94; Asghar, K; Souza, ED, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office: Washington, DC, 1989; pp 12–40. 282 kB.

Nichols, DE; Oberlender, R; Burris, K; Hoffman, AJ; Johnson, MP. Studies of dioxole ring substituted 3,4-methylenedioxyamphetamine (MDA) analogues. Pharmacol., Biochem. Behav., 1989, 34 (3), 571–576. 680 kB. doi:10.1016/0091-3057(89)90560-1

Steele, TD; Nichols, DE; Yim, GKW. MDMA transiently alters biogenic amines and metabolites in mouse brain and heart. Pharmacol., Biochem. Behav., 1989, 34 (2), 223–227. 477 kB. doi:10.1016/0091-3057(89)90303-1

Buchanan, JF; Brown, CR. ‘Designer drugs’. A problem in clinical toxicology. Med. Toxicol. Adverse. Drug. Exp., 1988, 3 (1), 1–17.

Gerdes, JM; Mathis, CA; Shulgin, AT. Synthesis of 1-[2′,5′-dimethoxy-4′-(p-β-fluoroethyl)phenyl]-2-aminopropane: Studies related to 18F-labeled serotonin receptor ligands. Tetrahedron Lett., 1988, 129 (50), 6537–6540. 268 kB. doi:10.1016/S0040-4039(00)82391-6

Jacob, P; Benowitz, NL; Shulgin, AT. Recent studies of nicotine metabolism in humans. Pharmacol., Biochem. Behav., 1988, 30 (1), 249–253. 490 kB. doi:10.1016/0091-3057(88)90453-4

Jansen, KLR; Prast, CJ. Psychoactive properties of mitragynine (kratom). J. Psychoactive Drugs, 1988, 20 (4), 455–457. 2807 kB.

Nichols, DE; Lloyd, DH; Johnson, MP; Hoffman, AJ. Synthesis and serotonin receptor affinities of a series of enantiomers of α-methyltryptamines: Evidence for the binding conformation of tryptamines at serotonin 5-HT1B receptors. J. Med. Chem., 1988, 31 (7), 1406–1412. 1085 kB. doi:10.1021/jm00402a026

Jacob, P; Benowitz, NL; Shulgin, AT. Synthesis of optically pure deuterium-labelled nicotine, nornicotine and cotinine. J. Labelled Comp. and Radiopharm., 17 Aug 1987, 25 (10), 1117–1128. 593 kB. doi:10.1002/jlcr.2580251009

McKenna, DJ; Mathis, CA; Shulgin, AT; Sargent, T; Saavedra, JM. Autoradiographic localization of binding sites for 125I-DOI, a new psychotomimetic radioligand, in the rat brain. Eur. J. Pharmacol., 1987, 137 (2–3), 289–290. 232 kB. doi:10.1016/0014-2999(87)90239-1

Sargent, TW; Shulgin, AT; Mathis, CA. Rapid brain scanning pharmaceutical. U. S. Patent 4,647,446, 1987. 619 kB.

Shulgin, AT; Jacob, P; Benowitz, NL; Lau, D. Identification and quantitative analysis of cotinine-N-oxide in human urine. J. Chromatogr. Biomed. Applic., 1987, 423, 365–372. 540 kB. doi:10.1016/0378-4347(87)80365-1

Mathis, CA; Shulgin, AT; Sargent, T. Synthesis of 122I- and 125I-labelled meta-dimethoxy-N,N-dimethyliodophenylisopropylamines. J. Labelled Comp. and Radiopharm., 1 Feb 1986, 23 (2), 115–125. 445 kB. doi:10.1002/jlcr.2580230202

Jacob, P; Benowitz, NL; Yu, L; Shulgin, AT. Determination of nicotine N-oxide by gas chromatography following thermal conversion to 2-methyl-6-(3-pyridyl)tetrahydro-1,2-oxazine. Anal. Chem., 1986, 58 (11), 2218–21. 7064 kB. doi:10.1021/ac00124a022

Mathis, CA; Shulgin, AT; Yano, Y; Sargent, T. 18F-Labelled N,N-dimethylamphetamine analogues for brain imaging studies. Appl. Radiat. Isot., 1986, 37 (8), 865–872. 502 kB.

Menachery, MD; Lavanier, GL; Wetherly, ML; Guinaudeau, H; Shamma, M. Simple isoquinoline alkaloids. J. Nat. Prod., 1986, 49 (5), 745–778. 1488 kB. doi:10.1021/np50047a001

Nichols, DE. Studies of the relationship between molecular structure and hallucinogenic activity. Pharmacol., Biochem. Behav., 1986, 24 (2), 335–340. 542 kB. doi:10.1016/0091-3057(86)90362-X

Nichols, DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: Entactogens. J. Psychoactive Drugs, 1986, 18 (4), 305–313. 10675 kB.

Nichols, DE; Hoffman, AJ; Oberlender, RA; Jacob, P; Shulgin, AT. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: Representatives of a novel therapeutic class. J. Med. Chem., 1986, 29 (10), 2009–2015. 1024 kB. doi:10.1021/jm00160a035

Nichols, DE; Hoffman, AJ; Oberlender, RA; Riggs, RM. Synthesis and evaluation of 2,3-dihydrobenzofuran analogs of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane: Drug discrimination studies in rats. J. Med. Chem., 1986, 29 (2), 302–304. 441 kB. doi:10.1021/jm00152a022

Shulgin, AT. The background and chemistry of MDMA. J. Psychoactive Drugs, 1986, 18 (4), 291–304. 13190 kB.

Hoffman, AJ; Nichols, DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. J. Med. Chem., 1985, 28 (9), 1252–1255. 583 kB. doi:10.1021/jm00147a022

Lemaire, D; Jacob, P; Shulgin, AT. Ring substituted beta-methoxyphenethylamines: a new class of psychotomimetic agents active in man. J. Pharm. Pharmacol., 1985, 37 (8), 575–7. 3740 kB.

Mathis, CA; Sargent, T; Shulgin, AT. Iodine-122-labeled amphetamine derivative with potential for PET brain blood-flow studies. J. Nucl. Med., 1985, 26 (11), 1295–1301. 1182 kB.

Repke, DB; Grotjahn, DB; Shulgin, AT. Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents. J. Med. Chem., 1985, 28 (7), 892–896. 711 kB. doi:10.1021/jm00145a007

Jacob, P; Savanapridi, C; Yu, L; Wilson, M; Shulgin, AT; Benowitz, NL; Elias-Baker, BA; Hall, SM; Herning, RI. Ion-pair extraction of thiocyanate from plasma and its gas chromatographic determination using on-column alkylation. Anal. Chem., 1984, 56 (9), 1692–5. 577 kB. doi:10.1021/ac00273a036

Jacob, P; Shulgin, AT. Sulfur analogs of psychotomimetic agents. 3. Ethyl homologs of mescaline and their monothioanalogs. J. Med. Chem., 1984, 27 (7), 881–887. 1213 kB. doi:10.1021/jm00373a013

McKenna, DJ; Towers, HHN. Biochemistry and pharmacology of tryptamines and beta-carbolines: A minireview. J. Psychoactive Drugs, 1984, 16 (4), 347–358. 10809 kB.

Nichols, DE; Jadhav, KP; Oberlender, RA; Zabik, JE; Bossart, JF; Hamada, A; Miller, DD. Synthesis and evaluation of substituted 2-phenylcyclobutylamines as analogs of hallucinogenic phenethylamines: Lack of LSD-like biological activity. J. Med. Chem., 1984, 27 (9), 1108–1111. 617 kB. doi:10.1021/jm00375a004

Oberlender, RA; Kothari, PJ; Nichols, DE; Zabik, JE. Substituent branching in phenethylamine-type hallucinogens: A comparison of 1-[2,5-dimethoxy-4-(2-butyl)phenyl]-2-aminopropane and 1-[2,5-dimethoxy-4-(2-methylpropyl)phenyl]-2-aminopropane. J. Med. Chem., 1984, 27 (6), 788–792. 764 kB. doi:10.1021/jm00372a015

Sargent, T; Shulgin, AT; Mathis, CA. New iodinated amphetamines by rapid synthesis for use as brain blood flow indicators. J. Labelled Comp. and Radiopharm., 1984, 19 (11–12), 1307–1. 4459 kB. doi:10.1002/jlcr.2580191102

Sargent, T; Shulgin, AT; Mathis, CA. Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography. J. Med. Chem., 1984, 27 (8), 1071–1077. 1859 kB. doi:10.1021/jm00374a023

Jacob, P; Shulgin, AT. Sulfur analogs of psychotomimetic agents. 2. Analogs of (2,5-dimethoxy-4-methylphenyl)- and of (2,5-dimethoxy-4-ethylphenyl)isopropylamine. J. Med. Chem., 1983, 26 (5), 746–752. 1054 kB. doi:10.1021/jm00359a021

Meyer, BN; Helfrich, JS; Nichols, DE; McLaughlin, JL; Davis, DV; Cooks, RG. Cactus alkaloids. LIII. Coryphanthine and O-methyl-candicine, two new quaternary alkaloids from Coryphantha greenwoodii. J. Nat. Prod., 1983, 45 (5), 688–639. 442 kB. doi:10.1021/np50029a017

Shulgin, AT. Twenty years on an ever-changing quest. In Psychedelic Reflections; Grinspoon,, L; Bakalar, JB, Eds., Human Sciences Press: New York, 1983; pp 205–212. 1649 kB.

Castagnoli,Neal, CCST. Studies on the chemical reactivity of the quinone methide derived from the oxidative cyclization of α-methyl-3,4-dihydroxyphenylalanine ethyl ester. J. Org. Chem., 1982, 47 (27), 5258-5262. 710 kB. doi:10.1021/jo00148a007

Hathaway, BA; Nichols, DE; Nichols, MB; Yim, GKW. A new, potent, conformationally-restricted analog of amphetamine: 2-amino-1,2-dihydronaphthalene. J. Med. Chem., 1982, 25 (5), 535–538. 563 kB. doi:10.1021/jm00347a011

Jacob, JN; Nichols, DE. Isomeric cyclopropyl ring-methylated homologs of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine, an hallucinogen analog. J. Med. Chem., 1982, 25 (5), 526–530. 732 kB. doi:10.1021/jm00347a009

Kline, TB; Benington, F; Morin, RD; Beaton, JM. Structure-activity relationships in potentially hallucinogenic N,N-dialkyltryptamines substituted in the benzene moiety. J. Med. Chem., 1982, 25 (8), 908–913. 845 kB. doi:10.1021/jm00350a005

Kline, TB; Benington, F; Morin, RD; Beaton, JM; Glennon, RA; Domelsmith, LN; Houk, KN; Rozeboom, MD. Structure-activity relationships for hallucinogenic N,N-dialkyltryptamines: photoelectron spectra and serotonin receptor affinities of methylthio and methylenedioxy derivatives. J. Med. Chem., 1982, 25 (11), 1381–1383. 378 kB. doi:10.1021/jm00353a021

Nichols, DE; Lloyd, DH; Hoffman, AJ; Nichols, MB; Yim, GKW. Effects of certain hallucinogenic amphetamine analogs on the release of [3H]-serotonin from rat brain synaptosomes. J. Med. Chem., 1982, 25 (5), 530–535. 804 kB. doi:10.1021/jm00347a010

Pummangura, S; McLaughlin, JL; Davis, DV; Cooks, RG. Cactus alkaloids. XLIX. New trace alkaloids (dehydrosalsolidine and heliamine) from the Saguaro, Carnegiea gigantea, and confirmation by MIKES (MS\MS). J. Nat. Prod., 1982, 45 (3), 277–282. 457 kB. doi:10.1021/np50021a008

Shulgin, AT; Jacob, P. Potential misrepresentation of 3,4-methylene-dioxyamphetamine (MDA). A toxicological warning. J. Anal. Tox., 1982, 6 (2), 71–75. 5581 kB.

Shulgin, AT; Jacob, P. 1-(3,4-Methylenedioxyphenyl)-3-aminobutane: A potential toxicological problem. Clin. Toxicol., 1982, 19 (1),109–110. 77 kB. doi:10.3109/15563658208990371

Domelsmith, LN; Eaton, TA; Houk, KN; Anderson, GM; Glennon, RA; Shulgin, AT; Castagnoli, N; Kollman, PA. Photoelectron spectra of psychotropic drugs. 6. Relationships between physical properties and pharmacological actions of amphetamine analogs. J. Med. Chem., 1981, 24 (12), 1414–1421. 963 kB. doi:10.1021/jm00144a009

Jacob, P; Shulgin, AT. Sulfur analogues of psychotomimetic agents. Monothio analogues of mescaline and isomescaline. J. Med. Chem., 1981, 24 (11), 1348–1353. 953 kB. doi:10.1021/jm00143a017

Kothari, PJ; Hathaway, BA; Nichols, DE; Yim, GKW. Synthesis and serotonin-like activity of 2-amino-5,8-dimethoxy-6-methyl-1,2-dihydronaphthalene. J. Med. Chem., 1981, 24 (7), 882–884. 464 kB. doi:10.1021/jm00139a022

Nichols, DE. Structure-activity relationships of phenethylamine hallucinogens. J. Pharm. Sci., 1981, 70 (8), 839–849. 1424 kB. doi:10.1002/jps.2600700802

Pummangura, S; McLaughlin, JL; Schifferdecker, RC. Cactus alkaloids. XLVII. β-Phenethylamines from the “Missouri Pincushion”, Coryphantha (Neobessya) missouriensis. J. Nat. Prod., 1981, 44 (5), 614–616. 261 kB. doi:10.1021/np50017a022

Repke, DB; Ferguson, WJ; Bates, DK. Psilocin analogs II. Synthesis of 3-[2-(dialkylamino)ethyl]-, 3-[2-(N-methyl-N-alkylamino)ethyl]-, and 3-[2-(cycloalkylamino)ethyl]indol-4-ols. J. Heterocycl. Chem., 1981, 18 (1), 175–179. doi:10.1002/jhet.5570180131

Shulgin, AT. Profiles of psychedelic drugs. 11. Bufotenine. J. Psychoactive Drugs, 1981, 13 (4), 389. 848 kB.

Shulgin, AT. Profiles of psychedelic drugs. 10. DOB. J. Psychoactive Drugs, 1981, 13 (1), 99. 775 kB.

Shulgin, AT; Carter, MF. N,N-diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun. Psychopharmacol., 1981, 4 (5), 363–369.

Braun, U; Shulgin, AT; Braun, G. Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine). J. Pharm. Sci., 1980, 69 (2), 192–195. 513 kB. doi:10.1002/jps.2600690220

Cannon, JG; Perez, JA; Pease, JP; Long, JP; Flynn, JR; Rusterholz, DB; Dryer., SE. Comparison of biological effects of N-alkylated congeners of beta-phenethylamine derived from 2-aminotetralin, 2-aminoindan, and 6-aminobenzocycloheptene. J. Med. Chem., 1980, 23 (7), 745–749. 731 kB. doi:10.1021/jm00181a009

Shulgin, AT. Profiles of psychedelic drugs. 9. LSD. J. Psychedelic Drugs, 1980, 12 (2), 173–174. 1025 kB.

Shulgin, AT. Profiles of psychedelic drugs. 8. Psilocybin. J. Psychedelic Drugs, 1980, 12 (1), 79. 822 kB.

Standridge, RT; Howell, HG; Tilson, HA; Chamberlain, JH; Holava, HM; Gylys, JA; Partyka, RA; Shulgin, AT. Phenylalkylamines with potential psychotherapeutic utility. 2. Nuclear substituted 2-amino-1-phenylbutanes. J. Med. Chem., 1980, 23 (2), 154–162. 1125 kB. doi:10.1021/jm00176a010

Weintraub, HJR; Nichols, DE; Makriyannis, A; Fesik, SW. Conformational energy differences between side chain alkylated analogs of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane. J. Med. Chem., 1980, 23 (3), 339–341. 452 kB. doi:10.1021/jm00177a030

Woolverton, WL; Shybut, G; Johanson, CE. Structure-activity relationships among some d-N-alkylated amphetamines. Pharmacol., Biochem. Behav., 1980, 13 (6), 869–876. 783 kB. doi:10.1016/0091-3057(80)90221-X

Chilton, WS; Bigwood, J; Jensen, RE. Psilocin, Bufotenine and serotonin: Historical and biosynthetic observations. J. Psychoactive Drugs, 1979, 11 (1–2), 61–69. 9523 kB.

Glennon, RA; Gessner, PK. Serotonin receptor binding affinities of tryptamine analogs. J. Med. Chem., 1979, 22 (4), pp 428–432. 731 kB. doi:10.1021/jm00190a014

Glennon, RA; Kier, LB; Shulgin, AT. Molecular connectivity analysis of hallucinogenic mescaline analogs. J. Pharm. Sci., 1979, 68 (7), 906–907. 252 kB. doi:10.1002/jps.2600680733

Nichols, DE; Kostuba, LJ. Steric effects of substituents on phenethylamine hallucinogens. 3,4-(Methylenedioxy)amphetamine analogs alkylated on the dioxole ring. J. Med. Chem., 1979, 22 (10), 1264–1267. 606 kB. doi:10.1021/jm00196a022

Nichols, DE; Woodard, R; Hathaway, BA; Lowy, MT; Yim, GKW. Resolution and absolute configuration of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine, a potent hallucinogen analog. J. Med. Chem., 1979, 22 (4), 458–460. 464 kB. doi:10.1021/jm00190a021

Shulgin, AT. Profiles of psychedelic drugs. 6. α,O-DMS. J. Psychedelic Drugs, 1979, 11 (3), 247. 684 kB.

Shulgin, AT. Profiles of psychedelic drugs. 7. Mescaline. J. Psychedelic Drugs, 1979, 11 (4), 355. 713 kB.

Shulgin, AT. Chemistry of phenethylamines related to mescaline. J. Psychedelic Drugs, 1979, 11 (1–2), 41–52. 11326 kB.

Anderson, GM; Braun, G; Braun, U; Nichols, DE; Shulgin, AT. Absolute configuration and psychotomimetic activity. In QuaSAR: Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens. NIDA Research Monograph 22; Barnett, G; Trsic, M; Willette, RE, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office: Washington, DC, 1978; pp 8–15. 457 kB.

Anderson, GM; Castagnoli, N; Kollman, PA. Quantitative structure-activity relationships in the 2,4,5-ring-substituted phenylisopropylamines. In QuaSAR: Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens. NIDA Research Monograph 22; Barnett, G; Trsic, M; Willette, RE, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office: Washington, DC, 1978; pp 199–217. 623 kB.

Barfknecht, CF; Caputo, JF; Tobin, MB; Dyer, DC; Standridge, RT; Howell, HG; Goodwin, WR; Partyka, RA; Gylys, JA; Cavanagh, RL. Congeners of DOM: Effect of distribution on the evaluation of pharmacologic data. In QuaSAR: Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens. NIDA Research Monograph 22; Barnett, G; Trsic, M; Willette, RE, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office: Washington, DC, 1978; pp 16–26. 502 kB.

Bielt, JH; Bopp, BA. Amphetamines: Structure-activity relationships. In Handbook of Psychopharmacology: Stimulants; Iversen, LL; Iversen, SD; Snyder, SH, Eds., Plenum Press: New York, 1978; Vol. 11, pp 1–39. 12059 kB.

Braun, G; Shulgin, AT; Sargent, T. Synthesis of 123I-labelled 4-iodo-2,5-dimethoxyphenylisopropylamine. J. Labelled Comp. and Radiopharm., 1978, 14 (1), 767–773. 291 kB. doi:10.1002/jlcr.2580140515

Braun, U; Braun, G; Jacob, P; Nichols, DE; Shulgin, AT. Mescaline Analogs: Substitutions at the 4-Position. In QuaSAR: Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens. NIDA Research Monograph 22; Barnett, G; Trsic, M; Willette, RE, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office: Washington, DC, 1978; pp 27–37. 497 kB.

Castagnoli, N. Drug metabolism: Review of principles and the fate of one-ring psychotomimetics. In Handbook of Psychopharmacology: Stimulants; Iversen, LL; Iversen, SD; Snyder, SH, Eds., Plenum Press: New York, 1978; Vol. 11, pp 335–387. 21916 kB.

Fuller, RW. Structure-activity relationships among the halogenated amphetamines. Ann. N.Y. Acad. Sci., 1978, 305, 147–159. 730 kB. doi:10.1111/j.1749-6632.1978.tb31518.x

Nichols, DE; Pfister, WR; Yim, GRW. LSD and phenethylamine hallucinogens: New structural analogy and implications for receptor geometry. Life Sci., 1978, 22 (24), 2165–2170. 323 kB. doi:10.1016/0024-3205(78)90567-2

Nichols, DE; Weintraub, HJR; Pfister, WR; Yim, GKW. The use of rigid analogues to probe hallucinogen receptors. In QuaSAR: Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens. NIDA Research Monograph 22; Barnett, G; Trsic, M; Willette, RE, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office: Washington, DC, 1978; pp 70–83. 717 kB.

Partyka, RA; Standridge, RT; Howell, HG; Shulgin, AT. 2-Amino-1-(2,5-dimethoxyphenyl)butanes. U.S. Patent 4,105,695, issued Aug. 8, 1978. 645 kB.

Sargent, T; Braun, G; Braun, U; Budinger, TF; Shulgin, AT. Brain and retina uptake of a radio-iodine labeled psychotomimetic in dog and monkey. Commun. Psychopharmacol., 1978, 2 (1), 1–10.

Sargent, T; Budinger, TF; Braun, G; Shulgin, AT; Braun, U. An iodinated catecholamine congener for brain imaging and metabolic studies. J. Nucl. Med., 1978, 19 (1), 71–76. 922 kB.

Schultes, RE. Plants and plant constituents as mind-altering agents throughout history. In Handbook of Psychopharmacology: Stimulants; Iversen, LL; Iversen, SD; Snyder, SH, Eds., Plenum Press: New York, 1978; Vol. 11, pp 219–241. 11059 kB.

Shulgin, AT. Psychotomimetic drugs: structure-activity relationships. In Handbook of Psychopharmacology: Stimulants; Iversen, LL; Iversen, SD; Snyder, SH, Eds., Plenum Press: New York, 1978; Vol. 11, pp 243–333. 36161 kB.

Shulgin, AT; Nichols, DE. Characterization of three new psychotomimetics. In The Psychopharmacology of Hallucinogens; Stillman, RC; Willette, RE, Eds., Pergamon Press: New York, 1978; pp 74–84. 547 kB.

Braun, U; Shulgin, AT; Braun, G; Sargent, T. Synthesis and body distribution of several iodine-131-labeled central nervous system active drugs. J. Med. Chem., 1977, 20 (12), 1543–1546. 1124 kB. doi:10.1021/jm00222a001

Helisten, C; Shulgin, AT. The detection of 1-piperidinodydlohexanecarbonitrile contamination in illicit preparations of 1-(1-phenylcyclohexyl)piperidine and 1-(1-(2-thienyl)cyclohexyl)piperidine. J. Chromatogr., 1977, 117 (1), 232–235. 277 kB. doi:10.1016/S0021-9673(00)81090-0

Jacob, P; Anderson, G; Meshul, CK; Shulgin, AT; Castagnoli, N. Monomethylthio analogs of 1-(2,4,5-trimethoxyphenyl)-2-aminopropane. J. Med. Chem., 1977, 20 (10), 1235–1239. 717 kB. doi:10.1021/jm00220a001

Nichols, DE; Dyer, DC. Lipophilicity and serotonin agonist activity in a series of 4-substituted mescaline analogs. J. Med. Chem., 1977, 20 (2), 299–301. 409 kB. doi:10.1021/jm00212a022

Nichols, DE; Shulgin, AT; Dyer, DC. Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives. Life Sciences, 1977, 21 (4), 569–576. 320 kB.

Repke, DB; Ferguson, WJ; Bates, DK. Psilocin analogs. 1. Synthesis of 3-[2-(dialkylamino)ethyl]- and 3-[2-(cycloalkylamino)ethyl]indol-4-ols. J. Heterocycl. Chem., 1977, 14 (1), 71–74. doi:10.1002/jhet.5570140113

Shulgin, AT. Profiles of psychedelic drugs. 5. STP. J. Psychedelic Drugs, 1977, 9 (2), 171–172. 755 kB.

Shulgin, AT. Profiles of psychedelic drugs. 4. Harmaline. J. Psychedelic Drugs, 1977, 9 (1), 79–80. 1135 kB.

White, TJ; Goodman, D; Shulgin, AT; Castagnoli, N; Lee, R; Petrakis, NL. Mutagenic activity of some centrally active aromatic amines in Salmonella typhimurium. Mutat. Res., 1977, 56 (2), 199–202. 256 kB. doi:10.1016/0027-5107(77)90210-X

Bailey, K; Gagné, DR; Pike, RK. Investigation and identification of the bromination products of dimethoxyamphetamines. J. Assoc. Off. Anal. Chem., 1976, 59 (5), 1162–1169.

Desantis, F; Nieforth, KA. Synthesis of potential mescaline antagonists. J. Pharm. Sci., 1976, 65 (10), 1479–1484. 704 kB. doi:10.1002/jps.2600651016

Jacob, P; Callery, PS; Shulgin, AT; Castagnoli, N. Convenient synthesis of quinones from hydroquinone dimethyl ethers. Oxidative demethylation with ceric ammonium-nitrate. J. Org. Chem., 1976, 41 (22), 3627–3629. 457 kB. doi:10.1021/jo00884a035

Nichols, DE; Shulgin, AT. Sulfur analogs of psychotomimetic amines. J. Pharm. Sci., 1976, 65 (1), 1554–1556. 383 kB. doi:10.1002/jps.2600651040

Ranieri, RL; McLaughlin, JL. β-Phenethylamine and tetrahydroisoquinoline alkaloids from the Mexican cactus Dolichothele longjmamma. J. Org. Chem., 1976, 41 (2), 319–323. 840 kB. doi:10.1021/jo00864a030

Sargent, T; Shulgin, AT; Kusubov, N. Quantitative measurement of demethylation of [14]C-methoxyl labeled DMPEA and TMA-2 in rats. Psychopharmacol. Commun., 1976, 2 (3), 199–206. 8643 kB.

Shulgin, AT. Psychotomimetic agents. In Psychopharmacological Agents; Gordon, M, Ed., Academic Press: New York, 1976; Vol. 4, pp 59–146. 35119 kB.

Shulgin, AT. Profiles of psychedelic drugs. 1. DMT. J. Psychedelic Drugs, 1976, 8 (2), 167–168. 1208 kB.

Shulgin, AT. Profiles of psychedelic drugs. 2. TMA-2. J. Psychedelic Drugs, 1976, 8 (2), 169. 891 kB.

Shulgin, AT. Profiles of psychedelic drugs. 3. MMDA. J. Psychedelic Drugs, 1976, 8 (4), 331. 789 kB.

Shulgin, AT. Abuse of the term “amphetamines”. Clin. Toxicol., 1976, 9 (3), 351–352. 107 kB. doi:10.3109/15563657608988135

Shulgin, AT. On the term “Amphetamines”. Clin. Toxicol., 1976, 9 (3), 449. 25 kB. doi:10.3109/15563657608988144

Shulgin, AT; MacLean, DE. Illicit synthesis of phencyclidine (PCP) and several of its analogs. Clin. Toxicol., 1976, 9 (4), 553–560. 352 kB. doi:10.3109/15563657608988157

Standridge, RT; Howell, HG; Gylys, JA; Partyka, RA; Shulgin, AT. Phenylalkylamines with potential psychotherapeutic utility. 1. 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)butane. J. Med. Chem., 1976, 19 (12), 1400 –1404. 730 kB. doi:10.1021/jm00234a010

Sargent, T; Kalbhen, DA; Shulgin, AT; Braun, G; Stauffer, H; Kusubov, N. In vivo human pharmacodynamics of the psychodysleptic 4-Br-2,5-dimethoxyphenylisopropylamine labelled with 82Br or 77Br. Neuropharmacology, 1975, 14 (3), 165–174. 1157 kB.

Sargent, T; Kalbhen, DA; Shulgin, AT; Stauffer, H; Kusubov, N. A potential new brain-scanning agent: 4-77Br-2,5-dimethoxyphenylisopropylamine (4-Br-DPIA). J. Nucl. Med., 1975, 16 (3), 243–245. 443 kB.

Shulgin, AT. The chemical catalysis of altered states of consciousness. In Altered states of consciousness: current views and research problems; The Drug Abuse Council, Washington, DC, 1975; pp 123–134. 2230 kB.

Shulgin, AT. Drugs of abuse in the future. Clin. Toxicol., 1975, 8 (4), 405–456. 2507 kB. doi:10.3109/15563657508990076

Shulgin, AT; Carter, MF. Centrally active phenethylamines. Psychopharmacol. Commun., 1975, 1 (1), 93–98. 6175 kB.

Shulgin, AT; Dyer, DC. Psychotomimetic phenylisopropylamines. 5. 4-Alkyl-2,5-dimethoxyphenylisopropylamines. J. Med. Chem., 1975, 18 (12), 1201–1204. 534 kB. doi:10.1021/jm00246a006

Cimbura, G. PMA deaths in Ontario. Can. Med. Assoc. J., 8 Jun 1974, 110(8), 1263–1267.

Butterick, JR; Unrau, AM. Studies on theoretical psychotogens. Synthesis of O-methylated analogs of catecholamine neurotransmitters and metabolic precursors. Can. J. Chem., 1974, 52 (16), 2873–2879. 305 kB. doi:10.1139/v74-418

Naranjo, C. Ibogaine: Fantasy and reality. In The Healing Journey: New approaches to consciousness; Pantheon Books, New York, 1974; pp 174–228.

Nichols, DE; Barfknecht, CF; Long, JP; Standridge, RT; Howell, HG; Partyka, RA; Dyer, DC. Potential psychotomimetics. 2. Rigid analogs of 2,5-dimethoxy-4-methylphenylisopropylamine (DOM, STP). J. Med. Chem., 1974, 17 (2), 161–166. 718 kB. doi:10.1021/jm00248a004

Wolters, RJ; Bej, AJ; Tanner, NS. Conformationally constrained analogs of mescaline. J. Pharm. Sci., 1974, 63 (1), 1379–1382. 451 kB. doi:10.1002/jps.2600630909

Barfknecht, CF; Nichols, DE; Rusterholz, DB; Long, JP; Engelbrecht, JA; Beaton, JM; Bradley, RJ; Dyer, DC. Potential psychotomimetics. 2-Amino-1,2,3,4-tetrahydronaphthalene analogs. J. Med. Chem., 1973, 16, (7), 804–808. 614 kB. doi:10.1021/jm00265a013

Coutts, RT; Malicky, JL. The synthesis of some analogs of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM). Can. J. Chem., 1973, 51 (9), 1402–1409. 746 kB. doi:10.1139/v73-210

Nichols, DE; Barfknecht, CF; Rusterholz, DB; Benington, F; Morin, RD. Asymmetric synthesis of psychotomimetic phenylisopropylamines. J. Med. Chem., 1973, 16 (5), 480–483. 515 kB. doi:10.1021/jm00263a013

Shulgin, AT. Mescaline: the chemistry and pharmacology of its analogs. Lloydia, 1973, 36 (1), 46–58. 34766 kB.

Shulgin, AT. The narcotic pepper—The chemistry and pharmacology of Piper methysticum and related species. Bull. Narc., 1973, 25 (2), 61–77.

Barfknecht, CF; Nichols, DE. Effects of S-(+)- and R-(-)-3,4,dimethoxyphenylisopropylamines in the rat. J. Med. Chem., 1972, 15 (1), 109–110. 295 kB. doi:10.1021/jm00271a037

Chapman, NB; Scrowston, RM; Sutton,, TM. Synthesis of the sulphur analogue of psilocin and some related compounds. J. Chem. Soc., Perkin Trans., 1972, 1, 3011. 731 kB. doi:10.1039/P19720003011

Barfknecht, CF; Nichols, DE. Potential psychotomimetics. Bromomethoxyamphetamines. J. Med. Chem., 1971, 14 (4), 370–372. 377 kB. doi:10.1021/jm00286a026

Shulgin, AT. Chemistry and sources. In Drugs of Abuse: Their Genetic and other Chronic Nonpsychiatric Hazards; Epstein, SS, Ed., The MIT Press: Cambridge, MA, 1971; pp 3–26. 4292 kB.

Shulgin, AT; Sargent, T; Naranjo, C. 4-Bromo-2,5-dimethoxyphenylisopropylamine, a new centrally active amphetamine analog. Pharmacology, 1971, 5 (2), 103–107. 647 kB. doi:10.1159/000136181

Shulgin, AT. Chemistry and structure-activity relationships of the psychotomimetics. In Psychotomimetic Drugs; Efron, DH, Ed., Raven Press, New York, 1970; pp 21–41. 8647 kB.

Shulgin, AT. 4-Alkyl-dialkoxy-alpha-methyl-phenethylamines and their pharmacologically-acceptable salts. U. S. Patent 3,547,999, issued Dec. 15, 1970. 448 kB.

Snyder, SH; Weingartner, H; Faillace., LA. DOET (2,5-dimethoxy-4-ethylamphetamine) and DOM (STP) (2,5-dimethoxy-4-methylamphetamine), new psychotropic agents: Their effects in man. In Psychotomimetic Drugs; Efron, DH, Ed., Raven Press, New York, 1970; pp 247–264. 2550 kB.

Szara, S. DMT (N,N-dimethyltryptamine) and homologues: Clinical and pharmacological considerations. In Psychotomimetic Drugs; Efron, DH, Ed., Raven Press, New York, 1970; pp 275–286. 1897 kB.

Hollister, LE; Macnicol, MF; Gillespie, HK. An hallucinogenic amphetamine analog (DOM) in man. Psychopharmacology, 1 Jan 1969, 14 (1), 62–73. 667 kB. doi:10.1007/BF00401535

Lee, FGH; Daly, JW; Manian, AA. Synthesis of o-methylnordehydrobufotenine, a new psychoactive indole. J. Med. Chem., 1969, 12 (2), 321–322. 282 kB. doi:10.1021/jm00302a030

Naranjo, C. Psychotherapeutic Possibilities of New Fantasy-Enhancing Drugs. Clin. Toxicol., 1969, 2 (2), 209–224. 855 kB. doi:10.3109/15563656908990930

Shulgin, AT. Psychotomimetic agents related to the catecholamines. J. Psychedelic Drugs, 1969, 2 (2), 12–26. 11817 kB.

Shulgin, AT. Recent developments in cannabis chemistry. J. Psychedelic Drugs, 1969, 2 (1), 15–29. 10079 kB.

Shulgin, AT; Sargent, T; Naranjo, C. Structure-activity relationships of one-ring psychotomimetics. Nature, 1969, 221, 537–541. 537 kB. doi:10.1038/221537a0

Shulgin, AT; Sargent, T; Naranjo, C. Structure-activity relationships of one-ring psychotomimetics: Correction. Nature, 1969, 221 (5182), 786. 116 kB. doi:10.1038/221786f0

Snyder, SH; Richelson, E. Psychedelic drugs: Steric factors that predict psychotropic activity. Proc. Natl. Acad. Sci., 1 May 1968, 60 (1), 206–213. 881 kB.

Leung, AY; Paul, AG. Baeocystin and norbaeocystin: New analogs of psilocybin from Psilocybe baeocystis. J. Pharm. Sci., 1968, 57 (10), 1667–1671. 399 kB. doi:10.1002/jps.2600571007

Shulgin, AT. Ethyl homologs of 2,4,5-trimethoxyphenylisopropylamine. J. Med. Chem., 1968, 11 (1), 186–187. 242 kB. doi:10.1021/jm00307a056

Shulgin, AT. Convenient synthesis of myristicinaldehyde. Can. J. Chem., 1968, 46 (1) 75–77. 194 kB. doi:10.1139/v68-013

Faillace, LA; Vourlekis, A; Szara, S. Clinical evaluation of some hallucinogenic tryptamine derivatives. J. Nerv. Ment. Dis., 1967, 145 (4), 306–313. 635 kB.

Naranjo, C; Shulgin, AT; Sargent, T. Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy. Med. Pharmacol. Exp., 1967, 17, 359–364. doi:10.1159/000137100

Sargent, TW; Israelstam, DM; Shulgin, AT; Landaw, SA; Finley, NN. A note concerning the fate of the 4-methoxyl group in 3,4-dimethoxyphenethylamine (DMPEA). Biochem. Biophys. Res. Commun., 1967, 29 (1), 126–130. 262 kB. doi:10.1016/0006-291X(67)90552-9

Shulgin, AT. The separation and identification of the components of the aromatic ether fraction of essential oils by gas-liquid chromatography. J. Chromatogr., 1967, 30, 54–61. 769 kB. doi:10.1016/S0021-9673(00)84112-6

Shulgin, AT; Sargent, T. Psychotropic phenylisopropylamines derived from apiole and dillapiole. Nature, 1967, 215, 1494–1495. 262 kB. doi:10.1038/2151494b0

Baker, AW; Shulgin, AT. Solvent stabilization of conformers in o-iodophenol. Spectrochim. Acta, 1966, 22 (1), 95–105. 839 kB.

Leung, AY; Paul, AG. Baeocystin, a mono-methyl analog of psilocybin from Psilocybe baeocystis saprophytic culture. J. Pharm. Sci., 1966, 56 (1), 146. 101 kB. doi:10.1002/jps.2600560132

Shulgin, AT. The six trimethoxyphenylisopropylamines (trimethoxyamphetamines). J. Med. Chem., 1966, 9 (3), 445–456. 362 kB. doi:10.1021/jm00321a058

Shulgin, AT. Possible implication of myristicin as a psychotropic substance. Nature, 1966, 210, 380–384. 707 kB. doi:10.1038/210380a0

Shulgin, AT; Kerlinger, HO. The carbonyl double bond: A new hydrogen bond receptor. Chem. Commun. (London), 1966, 249–250. 175 kB. doi:10.1039/C19660000249

Shulgin, AT; Sargent, T; Naranjo, C. Role of 3,4-dimethoxyphenethylamine in schizophrenia. Nature, 1966, 212, 1606–1607. 267 kB. doi:10.1038/2121606a0

Baker, AW; Shulgin, AT. Enthalpies of intramolecular halogen–hydroxyl interactions. Can. J. Chem., 1965, 43 (3), 650–659. 445 kB. doi:10.1139/v65-083

Baker, AW; Shulgin, AT. Preferred repulsive interaction: A novel halogen-hydroxyl interaction. Nature, 1965, 206 (4985), 712. 244 kB. doi:10.1038/206712a0

Kaeding, WW; Shulgin, AT; Kenaga, EE. Carbamate insecticides - alkyl- and amino-substituted phenyl N-methylcarbamate insecticides. J. Agric. Food Chem., 1965, 13 (3), 215. 441 kB. doi:10.1021/jf60139a007

Shulgin, AT. Synthesis of the trimethoxyphenylpropenes. Can. J. Chem., 1965, 43 (12), 3437–3440. 295 kB. doi:10.1139/v65-478

Shulgin, AT; Kerlinger, HO. Structures of photochemical decomposition products of 2,5-di-t-butyl-p-benzoquinone. Tetrahedron Lett., 1965, 38, 3355. 170 kB. doi:10.1016/S0040-4039(00)71067-7

Baker, AW; Kerlinger, HO; Shulgin, AT. Temperature dependency of phenol νOH band absorptivities. Applications to enthalpy calculations. Spectrochim. Acta, 1964, 20 (10), 1467–1476. 712 kB.

Baker, AW; Kerlinger, HO; Shulgin, AT. The hydroxyl stretching bands of phenols: Some aspects of half-band widths. Spectrochim. Acta, 1964, 20 (10), 1477–1486. 656 kB.

Baker, AW; Shulgin, AT. Conformers of o-cis-propenyl phenols. Spectrochim. Acta, 1964, 20 (2), 153–158. 502 kB.

Shulgin, AT. Psychotomimetic amphetamines: Methoxy 3,4-dialkoxyamphetamines. Experientia, 1964, 20 (7), 366–367. 240 kB. doi:10.1007/BF02147960

Shulgin, AT. 3-Methoxy-4,5-methylenedioxy amphetamine, a new psychotomimetic agent. Nature, 1964, 201, 1120–1121. 212 kB. doi:10.1038/2011120a0

Shulgin, AT. Separation and analysis of methylated phenols as their trifluoroacetate ester derivatives. Anal. Chem., 1964, 36 (4), 920–921. doi:10.1021/ac60210a001

Shulgin, AT; Kerlinger, HO. Isolation of methoxyeugenol and trans-isoelemicin from oil of nutmeg. Naturwissenschaften, 1964, 51 (15), 360–361. 330 kB. doi:10.1007/BF00637880

Baker, AW; Shulgin, AT. Intramolecular hydrogen bonding in ortho trityl phenols. Spectrochim. Acta, 1963, 19 (9), 1611–1621. 347 kB.

Mckay, JB; Parkhursrt, RM; Silversteinax, M; Skinne, DWA. Analogues of psilocin and lysergic acid diethylamide. I. Chloro, nitro, and amino derivatives of 3-substituted indoles. Can. J. Chem., 1963, 41 (10), 2585–2590. 249 kB. doi:10.1139/v63-378

Shulgin, AT. Psychotomimetic agents related to mescaline. Experientia, 1963, 19 (3), 127–128. 264 kB. doi:10.1007/BF02171586

Shulgin, AT. Composition of the myristicin fraction from oil of nutmeg. Nature, 1963, 197, 379. 107 kB. doi:10.1038/197379a0

Shulgin, AT; Baker, AW. Solvent effects on Claisen rearrangement of β-methylallyl phenyl ether. J. Org. Chem., 1963, 28 (9), 2468. 257 kB. doi:10.1021/jo01044a521

Szara, S; Hearst, E; Putney, F. Metabolism and behavioural action of psychotropic tryptamine homologues. Int. J. Neuropharmacol., 1 Nov 1962, 1 (1–3), 111–117. 1056 kB. doi:10.1016/0028-3908(62)90015-1

Kaeding, WW; Shulgin, AT. Preparation of salicylic acids by hydroxylation of benzoic acids. J. Org. Chem., 1962, 27 (10), 3551. 473 kB. doi:10.1021/jo01057a035

Shulgin, AT. Baeyer-Villiger condensation. 1. ortho-Tritylation of phenols. J. Org. Chem., 1962, 27 (11), 3868. 585 kB. doi:10.1021/jo01058a026

Shulgin, AT; Bunnell, S; Sargent, T. The psychotomimetic properties of 3,4,5-trimethoxyamphetamine. Nature, 1961, 189, 1011–1012. 306 kB. doi:10.1038/1891011a0

Shulgin, AT; Kerlinger, HO. Isolation and characterization of a phenol half-salt. J. Org. Chem., 1960, 25 (11), 2037–2039. 353 kB. doi:10.1021/jo01081a605

Smythies, JR; Levy, CK. The comparative psychopharmacology of some mescaline analogues. J. Mental Sci., 1960, 106 (443), 531–536. 637 kB. doi:10.1192/bjp.106.443.531

Böszörményi, Z; Dér, P. Observations on the psychotogenic effect of N,N diethyltryptamine, a new tryptamine derivative. J. Mental Sci., 1959, 105 (438), 171–181. 1388 kB. doi:10.1192/bjp.105.438.171

Baker, AW; Shulgin, AT. Intramolecular hydrogen bonding. 2. The determination of Hammett sigma-constants by intramolecular hydrogen bonding in Schiff’s bases. J. Am. Chem. Soc, 1959, 81 (7), 1523–1529. 775 kB. doi:10.1021/ja01516a001

Baker, AW; Shulgin, AT. Physical and chemical effects of substituent groups on multiple bonds. 1. Methyl substituted olefins. J. Am. Chem. Soc, 1959, 81 (17), 4524–4528. 582 kB. doi:10.1021/ja01526a021

Baker, AW; Shulgin, AT. Intramolecular hydrogen bonds to π-electrons and other weakly basic groups. J. Am. Chem. Soc, 1958, 80 (20), 5358–5363. 672 kB. doi:10.1021/ja01553a010

Shulgin, AT; Baker, AW. Determination of Hammett sigma constants by intramolecular hydrogen bonding. Nature, 1958, 182 (4645), 1299–1299. 102 kB. doi:10.1038/1821299a0

Wasson, RG. Seeking the Magic Mushroom. LIFE, 14 May 1957, 101–120.

Szara, S. Dimethyltryptamin: Its metabolism in man; the relation to its psychotic effect to the serotonin metabolism. Experientia, 1956, 12 (11), 441–442. 333 kB. doi:10.1007/BF02157378

Peretz, DI; Smythies, JR; Gibson, WC. A new hallucinogen: 3,4,5-Trimethoxyphenyl-β-aminopropane. With notes on the stroboscopic phenomenon. J. Mental Sci., 1955, 101 (423), 317–329. 1559 kB. doi:10.1192/bjp.101.423.317

Shulgin, AT. Absence of rearrangement in the bromination of sec-butyl alcohol. J. Am. Chem. Soc, 1955, 77 (8), 2338–2339. 281 kB. doi:10.1021/ja01613a099

Shulgin, AT; Gal, EM. A new synthesis of 2 : 5-dihydroxyphenyl-DL-alanine adapted to isotopic scale. J. Chem. Soc., 1953, 267, 1313–1321. 989 kB. doi:10.1039/JR9530001313

Lien, OG; Shulgin, AT; Gal, EM; Greenberg, DM. Feasibility of quantitative separation of the threo- and erythro-forms of amino-acids by column chromatography. Nature, 1952, 169 (4304) 707. 101 kB. doi:10.1038/169707a0

Shulgin, AT; Lien, OG; Gal, EM; Greenberg, DM. Synthesis and chromatographic separation of isotopically labeled DL-threonine and DL-allothreonine. J. Am. Chem. Soc, 1952, 74 (9), 2427–2429. 374 kB. doi:10.1021/ja01129a081

Gal, EM; Shulgin, AT. Improved syntheses of C14-labeled malonic acid and malononitrile. J. Am. Chem. Soc, 1951, 73 (6), 2938–2939. 278 kB. doi:10.1021/ja01150a506

Saunders, N. E for Ecstasy. In Appendix 4: Annotated Bibliography; Nicholas Saunders, 14 Neal’s Yard, London, 0000; .

Shulgin, AT. Drug testing for mushrooms. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics.

Shulgin, AT. Illegal research. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics.

Shulgin, AT. Nomenclature. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics.

Shulgin, AT. Repeal the criminal drug laws. @ Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics.